Gross Margin % is calculated as gross profit divided by its revenue. OpGen's Gross Profit for the
three
months ended in Sep. 2023 was $0.01 Mil. OpGen's Revenue for the
three
months ended in Sep. 2023 was $0.70 Mil. Therefore, OpGen's Gross Margin % for the quarter that ended in Sep. 2023 was 1.00%.
The historical rank and industry rank for OpGen's Gross Margin % or its related term are showing as below:
OPGN'
s Gross Margin % Range Over the Past 10 Years
Min: -31.34 Med: 35.57 Max: 76.95
Current: 6.65
During the past 10 years, the highestGross Margin % of OpGen was 76.95%. The lowest was -31.34%. And the median was 35.57%.
OPGN's Gross Margin % is ranked worse than 94.1% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 53.575
vs OPGN: 6.65
OpGen had a gross margin of 1.00% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for OpGen was 0.00% per year.
OpGen Gross Margin % Historical Data
The historical data trend for OpGen's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, OpGen's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OpGen's Gross Margin % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OpGen's Gross Margin % distribution charts can be found below:
* The bar in red indicates where OpGen's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
OpGen (NAS:OPGN) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
OpGen had a gross margin of 1.00% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
OpGen Gross Margin % Related Terms
Thank you for viewing the detailed overview of OpGen's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OPGN has been successfully added to your 